141 results about "Messenger RNA" patented technology

The invention relates to the technical field of biological information, and discloses a messenger RNA stability prediction method, model, device, equipment and medium, the method comprises the following steps: obtaining target sequence information of a target messenger RNA; acquiring at least two of the following target feature information based on the target sequence information by using a feature extraction module in the messenger RNA stability prediction model: first sequence feature information, Kozak sequence feature information, Motif attention feature information and manual feature information; and predicting the stability of the target messenger RNA based on the target feature information by using a prediction head in the messenger RNA stability prediction model. According to the method, the mRNA stability is predicted by fusing the universal sequence feature of the mRNA, the Kozak sequence feature of the learnable position weight, the Motif attention feature based on the hash k-mer and the manual feature, and the accuracy of mRNA stability prediction is improved.

A composition of matter includes an antisense phosphorodiamidate morpholino oligomer (MO) that includes an MO base sequence. The MO base sequence is arranged to bind a corresponding complementary base sequence of messenger RNA (mRNA) transcribed from one or more genes for the beta subunit of human chorionic gonadotropin (hCG-β). An inventive method, for suppressing intracellular synthesis of a beta subunit of human chorionic gonadotropin (hCG-β), includes introducing such an MO into one or more cells.

Methods for interfering or controlling IFN induction, IFN production and / or IFN activity are disclosed, harnessing viral mechanisms for evading or suppressing host anti-viral immune reactions. These methods comprise administration of one or more viral messenger RNAs (mRNAs) coding for proteins or peptides that control or interfere with signal transduction upstream and / or downstream of IFN induction, thereby providing a means for preventing or treating diseases, disorders or conditions associated with increased IFN production, such as cancer, autoimmune diseases, inflammatory diseases and interferonopathies.

The present invention relates to compositions for in vitro and in vivo delivery of nucleic acids, in particular messenger RNAs (mRNAs), into a target cell and their applications. The present invention is directed to a composition comprising (A) at least one nucleic acid and (B) at least one lipid nanoparticle (LNP) comprising (i) at least one ionizable lipid; (ii) at least one phospholipid; (iii) at least one sterol, especially neutral sterol; (iv) at least one poly(ethyleneglycol)-lipid (PEG-lipid); and (v) an imidazolium-based cationic lipid of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9, Y and A− are as defined in the description. The present invention also relates to a method for in vitro or in vivo transfection of live cells and uses of said composition.

The invention relates to a dsRNA insecticide for preventing and treating thrips and a preparation method of the dsRNA insecticide. Belongs to the field of biotechnology and agricultural application. The dsRNA insecticide for preventing and treating the thrips is a preparation taking dsRNA as an effective component, and the dsRNA is of a double-stranded RNA structure containing a positive-sense strand and an antisense strand; the nucleotide sequence of the positive-sense strand is as shown in SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9 or SEQ ID NO. 11. The invention proves that dsACT and dsVATB can cause degradation of messenger RNA (Ribonucleic Acid) of ATP (Adenosine Triphosphate) enzyme coding genes in thrips and reduce the expression level of related genes; laboratory test and field efficacy test results jointly show that after the dsRNA insecticide is sprayed, the growth and development of the thrips are affected, individual death is further caused, and the achievement lays a good theoretical and application foundation for prevention and treatment of the thrips.

The present invention provides novel ionizable lipids and novel lipid nanoparticles comprising messenger RNA (mRNA) useful for the delivery of nucleic acids as defined herein, related pharmaceutical compositions or vaccines for use in human medicine or veterinary medicine, in particular for the treatment and / or prevention of cancer diseases.

The present invention provides, among other things, methods for purifying mRNA, which involves removing impurities from a messenger RNA preparation synthesized by large scale invitro transcription process (IVT), by precipitating the IVT-synthesized mRNA in a buffer comprising a denaturing salt in combination with a reducing agent, followed by capturing the precipitated mRNA and dissolving the captured mRNA into a solution to obtain purified mRNA.

A case for transporting a substance such as a messenger RNA vaccine, including a container, a damping material contained in the container and a storage structure immersed in the damping product, the storage structure forming cavities for receiving syringes containing said substance.

This application provides a method and apparatus for optimizing the codon sequence of human albumin, belonging to the field of data processing technology. Addressing the current problems of low synthesis efficiency and scarcity of human albumin drugs, it allows for the grouping of large datasets of human albumin amino acid sequences. An improved genetic optimization algorithm is then used to optimize the corresponding messenger RNA item by item, ultimately obtaining the optimal second target messenger RNA. When using this second target messenger RNA for protein expression to obtain the target recombinant human albumin, the expression efficiency of the host Pichia pastoris cells can be maximized, significantly improving the current synthesis efficiency of recombinant human albumin and greatly alleviating the problem of human albumin drug scarcity.

The present invention provides a pharmaceutical composition comprising an exosome encapsulating one or more cargo RNAs containing package RNA and one or more fusion proteins, wherein the nucleotide sequence of the package RNA is at least about 80%, about 85%, about 90%, about 95%, or about 100% identical to the nucleotide sequence of an elastin (ELN) gene or elastin messenger RNA (mRNA) also containing any isoform. Additionally, the present invention provides a method for treating an elastin deficiency-related disease in a subject using the pharmaceutical composition of the present invention.

An L-form ribonucleic acid (L-RNA) aptamer-antisense oligonucleotide (ASO) conjugate comprise the L-RNA aptamer, which comprises a ribonucleic acid sequence. The ASO comprises a deoxyribonucleic acid sequence selected from a group. A method of imaging amyloid precursor protein (APP) rG4 in a cell comprising transfecting the cell with a messenger RNA of APP, permeating the cell, contacting the permeated cell with a cyanine3 (Cy3) labeled APP nucleic acid probe and the L-RNA aptamer-ASO conjugate, and subjecting the product to fluorescence microscopy analysis to produce an image of the APP rG4 in the cell.

The present invention relates to lipid compounds, which can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids and / or their analogs, and / or lipid-conjugated polymers to form lipid nanoparticles for delivering therapeutic and / or prophylactic agents. In some instances, the lipid nanoparticles are used to deliver nucleic acids, such as messenger RNA and / or antisense RNA. Methods of using such lipid nanoparticles to treat and / or prevent various diseases are also provided. In one embodiment, a compound having the structure of formula (I) is provided: or a salt or an isomer or an N-oxide thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Pharmaceutical compositions comprising one or more of the compounds of the foregoing structural formula (I) and a therapeutic and / or prophylactic agent are also provided. In some embodiments, the pharmaceutical composition further comprises one or more components selected from neutral lipids, charged lipids, steroids and lipid-conjugated polymers. Such compositions are useful for forming lipid nanoparticles for delivering therapeutic and / or prophylactic agents. In other embodiments, the present invention provides a method of administering a therapeutic and / or prophylactic agent to a subject in need thereof, the method comprising preparing a pharmaceutical combination of a lipid nanoparticle comprising a compound of structural formula (I) and a therapeutic and / or prophylactic agent, and delivering the composition to the subject.

Synthetic bacterial messenger RNA can be used to make autologous, allogeneic or direct nucleic acid cancer vaccines. Cancer cells are transfected in vitro or in vivo with mRNA obtained from DNA encoding immunogenic bacterial proteins. The immune response to cancer is generated by direct administration of the mRNA in vivo or administration of a vaccine made from cancer cells in vitro. Codon modification of the mRNA can optimize expression of the immunogenic polypeptide in cancer cells.

Provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.

The present application relates to the technical field of biological information, and discloses a messenger RNA stability prediction method, model, device, equipment and medium, the method comprises the following steps: obtaining target sequence information of target messenger RNA; using the feature extraction module in the messenger RNA stability prediction model, at least two of the following target feature information is obtained based on the target sequence information: first sequence feature information, Kozak sequence feature information, Motif attention feature information and manual feature information; using the prediction head in the messenger RNA stability prediction model, predicting the stability of the target messenger RNA based on the target feature information. The present application predicts the mRNA stability by fusing the general sequence features of mRNA, the learnable position weight Kozak sequence features, the Motif attention features based on hash k-mer and the manual features, thereby improving the accuracy of mRNA stability prediction.

The present invention relates, in part, to methods for large-scale purification of mRNA. The method includes, at least, a step of centrifuging an mRNA suspension in a centrifuge comprising a porous substrate at a speed sufficient to remove process contaminants and to precipitate purified mRNA composition onto the porous substrate.

The subject invention provides a composition comprising an enomomer which comprises a) a carrier molecule, and b) at least one aptamer, wherein the carrier molecule is an antibody, an antigen-binding moiety, a serum protein, an intracellular protein, a messenger RNA (mRNA) or human serum albumin.

The present invention relates to compositions comprising RNA, preferably messenger RNA (mRNA), more preferably self-amplifying RNA (saRNA), and polymers, in particular cationic polymers, such as polyethylenimine (PEI), poly-L-Lysin (PEL), polyvinylamine (PVA) or polyallylamine (PAA), where individual RNA molecules are present in solution. In the formulations, the RNA is preferentially present in the form of monomers, dimers, timers or oligomers, but not as aggregates comprising a large number of RNA molecules per aggregate, in particular large polyplex nanoparticles. The formulations display improved transfection efficacy and they can be used for delivery of RNA to a subject, where they have an improved dose response relationship in comparison to formulations where large aggregates in the form of polyplex nanoparticles are present.

The present invention relates to a method for tailing in vitro transcribed (IVT) messenger RNA (mRNA) containing modified ribonucleotides, the method comprising adding the IVT mRNA to a tailing polymerase in a reaction buffer containing up to 30 mM of an alkali metal salt and at least 5 mM of a reducing agent.

The disclosure features compositions or systems and uses thereof, comprising a first polynucleotide encoding a target molecule, optionally a second polynucleotide encoding an effector, repressor, or endonuclease molecule; optionally a recognition or cleavage site in the first or second polynucleotide, and optionally a repressor / effector binding site in the first polynucleotide. The disclosure also features compositions or systems and uses thereof, comprising a messenger RNA (mRNA) comprising (i) an open reading frame encoding a polypeptide, and (ii) at least six miR142 target sites.

The present disclosure provides a method for treating angiogenesis in a target tissue in a subject. According to the present disclosure, there is provided a method which includes administering an immunogenic composition containing messenger RNA (mRNA) that encodes LRG1 or a fragment thereof to the subject.

Abstract The present invention relates to the mRNA vaccine of coronavirus spike protein with deletion of glycosites in the receptor binding domain (RBD), the subunit 1 (S1) domain, or the subunit 2 (S2) domain, or a combination thereof. The vaccine elicits broadly protective immune responses coronavirus and variants thereof. Abstract

Provided are methods of genetically modifying cells. In certain embodiments, the methods comprise modifying a coding region of a mitochondrial gene of the cell. According to some embodiments, the modification results in increased translation of a messenger RNA (mRNA) encoded by the mitochondrial gene by increasing the affinity of a codon-anti-codon interaction during translation of the mRNA as compared to the affinity of the codon-anti-codon interaction prior to the modifying. In certain embodiments, the modification results in decreased translation of an mRNA encoded by the mitochondrial gene by decreasing the affinity of a codon-anti-codon interaction during translation of the mRNA as compared to the affinity of the codon-anti-codon interaction prior to the modifying. Also provided are populations of the genetically modified cells, compositions comprising such populations, and methods of administering the compositions to a subject as a cell-based therapy.

The present invention relates to lipid compounds, which can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids and / or their analogues, and / or lipid-conjugated polymers to form lipid nanoparticles for delivering therapeutic and / or prophylactic agents. In some examples, the lipid nanoparticles are used to deliver nucleic acids, such as messenger RNA and / or antisense RNA. Methods of using such lipid nanoparticles to treat and / or prevent various diseases are also provided. In one embodiment, a compound having the structure of formula (I) is provided: or a salt or an isomer or an N-oxide thereof, wherein R 1 , R 2 as defined herein. There is also provided a pharmaceutical composition comprising one or more compounds of the foregoing structural formula (I) and a therapeutic and / or prophylactic agent. In some embodiments, the pharmaceutical composition further comprises one or more components selected from neutral lipids, charged lipids, steroids and lipid-conjugated polymers. Such compositions are useful for forming lipid nanoparticles for delivering therapeutic and / or prophylactic agents. In other embodiments, the present invention provides a method of administering a therapeutic and / or prophylactic agent to a subject in need thereof, the method comprising preparing a pharmaceutical combination of a lipid nanoparticle comprising a compound of structural formula (I) and a therapeutic and / or prophylactic agent, and delivering the composition to the subject.

The present disclosure relates to a method of determining the presence of at least one messenger RNA (mRNA) molecule in a composition, the method comprising: (a) reverse transcription of the at least one mRNA molecule to obtain a template comprising at least one first strand of complementary DNA (cDNA); (b) generating at least one double-stranded cDNA molecule from the template; (c) amplifying the at least one double-stranded cDNA molecule; (d) digesting the at least one amplified double-stranded cDNA molecule with at least one restriction enzyme to obtain a test cDNA fragment; (e) separating the test cDNA fragments so as to form a test cDNA fragment map; and (f) comparing the test cDNA fragment map to a control cDNA fragment map wherein the at least one mRNA molecule is present in the composition when the test cDNA fragment map comprises the control cDNA fragment map. Also disclosed are methods of quantifying and / or assessing the integrity of at least one mRNA molecule in a composition, processes of making a composition comprising at least one mRNA molecule and a primer pair for use in the methods of the invention.

The invention relates to lipid compounds which can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids and / or their analogues, and / or lipids conjugated with polymers to form lipid nanoparticles for delivering therapeutic and / or prophylactic agents. In some examples, the lipid nanoparticles are used for delivering nucleic acids such as messenger RNA and / or antisense RNA. Methods of using such lipid nanoparticles to treat and / or prevent various diseases are also provided. In one embodiment, a compound having the structure of formula (I) is provided: or a salt or an isomer or an N-oxide thereof, wherein R1, R2 and R3 are as defined herein. A pharmaceutical composition comprising one or more of the compounds of the foregoing structural formula (I) and a therapeutic and / or prophylactic agent is also provided. In some embodiments, the pharmaceutical composition further comprises one or more components selected from neutral lipids, charged lipids, steroids and lipids conjugated with polymers. Such compositions are useful for forming lipid nanoparticles for delivering therapeutic and / or prophylactic agents. In other embodiments, the invention provides a method of administering a therapeutic and / or prophylactic agent to a subject in need thereof, the method comprising preparing a pharmaceutical combination of a lipid nanoparticle comprising a compound of structural formula (I) and a therapeutic and / or prophylactic agent, and delivering the composition to the subject.

Disclosed herein are lipid nanoparticles comprising messenger RNA (mRNA) molecules encoding deepitoped Ara h 1 and / or de-epitoped Ara h 2, vaccines comprising the nanoparticles and methods for inducing desensitization to peanuts and / or immunomodulation of a response to peanuts in a subject allergic to peanuts.

The present invention relates generally to lipids, lipid nanoparticle formulations, and methods for their use in delivering nucleic acids, such as messenger RNA.

The present invention relates to lipid compounds which can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids and / or their analogues, and / or lipid-conjugated polymers to form lipid nanoparticles for delivering therapeutic and / or prophylactic agents. In some examples, the lipid nanoparticles are used for delivering nucleic acids such as messenger RNA and / or antisense RNA. Also provided are methods of using such lipid nanoparticles for treating and / or preventing various diseases. In one embodiment, a compound having the structure of formula (I) is provided: or a salt or an isomer or an N-oxide thereof, wherein R1 is as defined herein. Also provided is a pharmaceutical composition comprising one or more compounds of the foregoing structural formula (I) and a therapeutic and / or prophylactic agent. In some embodiments, the pharmaceutical composition further comprises one or more components selected from neutral lipids, charged lipids, steroids and lipid-conjugated polymers. Such compositions are useful for forming lipid nanoparticles for delivering therapeutic and / or prophylactic agents. In other embodiments, the present invention provides a method of administering a therapeutic and / or prophylactic agent to a subject in need thereof, the method comprising preparing a pharmaceutical combination of a lipid nanoparticle comprising a compound of structural formula (I) and a therapeutic and / or prophylactic agent, and delivering the composition to the subject.

The present disclosure provides RNA-lipid particles and formulations comprising novel lipids and therapeutic agents, methods of making RNA-lipid particles, and methods of delivering and / or administering RNA-lipid particles. In particular, the present disclosure provides RNA-lipid particles comprising a polyomithine-based lipid conjugate or conjugate of polyomithine and a lipid-like material, and RNA (e.g., single-stranded messenger RNA encoding a peptide or protein of interest), and methods of making RNA-lipid particles. Particles comprising mRNA and polyomithine are delivered to target tissues following administration via intramuscular, intravenous, or subcutaneous routes.